ATN 161
Alternative Names: Ac-PHSCN-NH2Latest Information Update: 05 Feb 2016
At a glance
- Originator Attenuon LLC
- Developer Attenuon; Tactic Pharma
- Class Antineoplastics; Peptides
- Mechanism of Action Angiogenesis inhibitors; Integrin alpha 5 beta 1 inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioma; Renal cancer
Most Recent Events
- 04 Feb 2016 Discontinued - Phase-I/II for Glioma (Recurrent) in USA (IV) before February 2016
- 04 Feb 2016 Discontinued - Phase-II for Renal cancer in USA (IV) before February 2016
- 31 May 2008 No development reported - Phase-I/II for Glioma (Recurrent) in USA (IV)